The Jill and Alan Miller Associate Professorship of Breast Cancer Excellence

Jill Miller

Established in 2013, the Professorship was created by Jill and Alan B. Miller to celebrate Jill’s 20th anniversary as a breast cancer survivor.

At Penn Medicine, Jill Miller has been an advocate for breast cancer research and patient care, and the chair supports a faculty member of the Abramson Cancer Center in the field of breast cancer medical oncology. The Millers have also established the Alan B. Miller Professorship at Wharton, where Mr. Miller earned his MBA. He is currently Chairman and CEO of Universal Health Services, Inc., which he founded in 1978 and led to become one of the largest and most respected hospital management companies in the nation. Mr. Miller also founded and serves as Chairman of the Board, CEO, and President of Universal Health Realty Income Trust. He has been a member of Wharton’s Graduate Executive Board and Board of Overseers.

The Millers generously support and serve on the boards of many medical, higher education, and arts organizations.


 

Angela M. DeMicheleCurrent Chairholder
Angela M. DeMichele, MD, MSCE

Angela M. DeMichele, MD, MSCE is a Professor of Medicine and Epidemiology at the Perelman School of Medicine and Co-Leader of the Breast Cancer Research Program and the 2-PREVENT Translational Center of Excellence (TCE) in the Abramson Cancer Center. She is also a Senior Scholar at the Center for Clinical Epidemiology and Biostatistics. Dr. DeMichele leads a translational clinical research program integrated with her clinical practice to develop breast cancer therapeutics and biomarkers through innovative trial designs that epitomize precision medicine.

Dr. DeMichele has authored over 100 manuscripts in high-impact journals and has been funded through NCI, the Komen Foundation, the Breast Cancer Research Foundation, the American Society of Clinical Oncology, and the American Cancer Society. She has been site Principal Investigator (PI) of over 30 investigator-initiated, industry, and cooperative group trials, Chair of Trial Operations for the I-SPY 2 multicenter neoadjuvant trial, and site PI for the Translational Breast Cancer Research Consortium. She also serves as Co-PI on two cooperative group-led, international registration trials of the CDK 4/6 inhibitor Palbociclib, and has been instrumental in the early phase development of this compound. As Co-Director of the 2-PREVENT Breast Cancer TCE, she leads a multidisciplinary team to tackle the problem of breast cancer recurrence through novel, multicenter basic research and clinical trials. Dr. DeMichele currently chairs the Breast Cancer Scientific Program Committee of the American Society of Clinical Oncology and is Associate Editor at Breast Cancer Research.